← Back to Clinical Trials
Recruiting NCT05895032

NCT05895032 Trial of an Exercise Intervention for Children With Haemophilia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05895032
Status Recruiting
Phase
Sponsor East Kent Hospitals University NHS Foundation Trust
Condition Hemophilia
Study Type INTERVENTIONAL
Enrollment 132 participants
Start Date 2021-05-06
Primary Completion 2025-06-30

Eligibility & Interventions

Sex Male only
Min Age 6 Years
Max Age 12 Years
Study Type INTERVENTIONAL
Interventions
ExerciseUsual Care

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 132 participants in total. It began in 2021-05-06 with a primary completion date of 2025-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

"Being able to participate in games and activities with their friends" is one of the things that matters most to boys with haemophilia. At present, there is a lack of robust evidence to determine whether muscle strengthening exercise can improve or negatively affect outcomes for young children with haemophilia. With the help of boys with haemophilia, their parents and physiotherapists the investigators have developed an exercise programme designed to increase muscle strength. Using this intervention the investigators will undertake a single-blinded, two-arm pragmatic randomised controlled trial (RCT) of a 12-week intervention verses usual care of boys with haemophilia aged 6-12 years of age.

Eligibility Criteria

Inclusion Criteria: • Children aged 6-12 years, with severe or moderate haemophilia A or B Exclusion Criteria: * von Willebrand disease * past history of fracture or trauma to the lower limb * orthopaedic surgery * acquired brain injury or any other disturbance of the central nervous system; joint or muscle bleed in the lower limb in the past 6 weeks * presence of lower limb pain or unable to fully comply with verbal instructions.

Contact & Investigator

Central Contact

David Stephensen, PhD

✉ david.stephensen@nhs.net

📞 01227783166

Principal Investigator

David Stephensen, PhD

STUDY CHAIR

East Kent Hospitals University NHS Foundation Trust

Frequently Asked Questions

Who can join the NCT05895032 clinical trial?

This trial is open to male participants only, aged 6 Years or older, up to 12 Years, studying Hemophilia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05895032 currently recruiting?

Yes, NCT05895032 is actively recruiting participants. Contact the research team at david.stephensen@nhs.net for enrollment information.

Where is the NCT05895032 trial being conducted?

This trial is being conducted at Canterbury, United Kingdom.

Who is sponsoring the NCT05895032 clinical trial?

NCT05895032 is sponsored by East Kent Hospitals University NHS Foundation Trust. The principal investigator is David Stephensen, PhD at East Kent Hospitals University NHS Foundation Trust. The trial plans to enroll 132 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology